# MONJUVI

NDC: 73535-208
Generic name: Tafasitamab-cxix
Labeler / Manufacturer: Incyte Corporation
Product type: HUMAN PRESCRIPTION DRUG
Marketing category: Biologic License Application
Dosage form: INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION
Routes: INTRAVENOUS
Marketing started: 20200805

FDA application: BLA761163

## Active ingredients

- TAFASITAMAB: 200 mg/5mL

## Pharmacological class

—

## External sources

- openFDA: https://api.fda.gov/drug/ndc.json?search=product_ndc:"73535-208"
- FDA NDC Directory: https://www.accessdata.fda.gov/scripts/cder/ndc/dsp_searchresult.cfm?p_ndc=73535-208
- DailyMed: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ec13ac6b-bfde-4e84-907a-83bd69584d95